SEARCH

SEARCH BY CITATION

References

  • 1
    Wymenga LF, Groenier K, Schuurman J, Boomsma JH, Elferink RO, Mensink HJA 2001 Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. Brit J Urol Int 88:231235.
  • 2
    Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M 2001 Biochemical markers for the detection of bone metastasis in patients with prostate cancer: Diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19:4551.
  • 3
    Noguchi M, Noda S 2001 Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166:11061110.
  • 4
    Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ 1983 Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51:918924.
  • 5
    Clarke NW, McClure J, George NJ 1991 Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68:7480.
  • 6
    Scher HI, Chung LW 1994 Bone metastases: Improving the therapeutic index. Semin Oncol 21:630656.
  • 7
    Roudier MP, Higano C, True L, Ott S, Penson D, Vessella R, Lange P 2001 Concordance between bone histology and technitium 99 methylene diophosphonate bone scan in advanced prostate cancer patients with special reference to bisphosphonate treatment. Cancer Res 42:793.
  • 8
    Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E, Fujita T 2000 Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267:632637.
  • 9
    Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:12351244.
  • 10
    Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E 2001 Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:1824.
  • 11
    Sanchez-Sweatman OH, Orr FW, Singh G 1998 Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 18:297305.
  • 12
    Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML 2002 Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94:1725.
  • 13
    Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:1345313458.
  • 14
    Chapman HA, Riese RJ, Shi GP 1997 Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59:6388.
  • 15
    Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaisse JM 1998 The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273:3234732352.
  • 16
    Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M, Sloane BF 1995 Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26:171178.
  • 17
    Szpaderska AM, Frankfater A 2001 An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61:34933500.
  • 18
    Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR 1994 Immunohistochemical analysis of cathepsins D. B, and L in human breast cancer. Hum Pathol 25:857862.
  • 19
    Yan S, Sameni M, Sloane BF 1998 Cathepsin B and human tumor progression. Biol Chem 379:113123.
  • 20
    Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, Bromme D, Gay S 1998 Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 25:18871894.
  • 21
    Dodds RA, Connor JR, Drake FH, Gowen M 1999 Expression of cathepsin K messenger RNA in giant cells and their precursors in human osteoarthritic synovial tissues. Arthritis Rheum 42:15881593.
  • 22
    Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, Bilbe G 1997 Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20:8186.
  • 23
    Buhling F, Gerber A, Hackel C, Kruger S, Kohnlein T, Bromme D, Reinhold D, Ansorge S, Welte T 1999 Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol 20:612619.
  • 24
    Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kukubo T, Inaoka T, Sloane J, Evans DB, Gallagher JA 1997 The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:53865390.
  • 25
    Diaz A, Willis AC, Sim RB 2000 Expression of the proteinase specialized in bone resorption, cathepsin K, in granulomatous inflammation. Mol Med 6:648659.
  • 26
    Buhling F, Waldburg N, Gerber A, Hackel C, Kruger S, Reinhold D, Bromme D, Weber E, Ansorge S, Welte T 2000 Cathepsin K expression in human lung. Adv Exp Med Biol 477:281286.
  • 27
    Tepel C, Bromme D, Herzog V, Brix K 2000 Cathepsin K in thyroid epithelial cells: Sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci 113:44874498.
  • 28
    Jokimaa V, Oksjoki S, Kujari H, Vuorio E, Anttila L 2001 Expression patterns of cathepsins B. H, K, L and S in the human endometrium. Mol Hum Reprod 7:7378.
  • 29
    Oksjoki S, Soderstrom M, Vuorio E, Anttila L 2001 Differential expression patterns of cathepsins B. H, K, L and S in the mouse ovary. Mol Hum Reprod 7:2734.
  • 30
    Corey E, Arfman EW, Liu AY, Vessella RL 1997 Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem 43:443452.
  • 31
    Aibe K, Yazawa H, Abe K, Teramura K, Kumegawa M, Kawashima H, Honda K 1996 Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. Biol Pharm Bull 19:10261031.
  • 32
    Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M 1996 Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:1251112516.
  • 33
    Blair HC, Sidonio RF, Friedberg RC, Khan NN, Dong SS 2000 Proteinase expression during differentiation of human osteoclasts in vitro. J Cell Biochem 78:627637.
  • 34
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT 2000 Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181186.
  • 35
    Ross RW, Small EJ 2002 Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:19521956.
  • 36
    Sinha AA, Gleason DF, DeLeon OF, Wilson MJ, Limas C, Reddy PK, Furcht LT 1991 Localization of type IV collagen in the basement membranes of human prostate and lymph nodes by immunoperoxidase and immuno alkaline phosphatase. Prostate 18:93104.
  • 37
    Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE 1994 Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem 19:232237.
  • 38
    Sinha AA, Gleason DF, Wilson MJ, Staley NA, Furcht LT, Palm SL, Reddy PK, Sibley RK, Martinez-Hernandez A 1989 Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate. Prostate 15:299313.
  • 39
    Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE 1995 Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 146:14981507.
  • 40
    Burns-Cox N, Avery NC, Gingell JC, Bailey AJ 2001 Changes in collagen metabolism in prostate cancer: a host response that may alter progression. J Urol 166:16981701.
  • 41
    Sinha AA, Jamuar MP, Wilson MJ, Rozhin J, Sloane BF 2001 Plasma membrane association of cathepsin B in human prostate cancer: Biochemical and immunogold electron microscopic analysis. Prostate 49:172184.
  • 42
    Waghray A, Keppler D, Sloane BF, Schuger L, Chen YQ 2002 Analysis of a truncated form of cathepsin H in human prostate tumor cells. J Biol Chem 277:1153311538.
  • 43
    Fernandez PL, Farre X, Nadal A, Fernandez E, Peiro N, Sloane BF, Shi GP, Chapman HA, Campo E, Cardesa A 2001 Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95:5155.
  • 44
    Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, Schnorr D, Loening SA 1999 Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 35:138144.
  • 45
    Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA, Lichtinghagen R 2002 Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 50:3845.
  • 46
    Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R 2001 Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 93:507515.
  • 47
    Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A 2000 Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:12481253.
  • 48
    Garnero P 2001 Markers of bone turnover in prostate cancer. Cancer Treat Rev 27:187192.
  • 49
    Lipton A, Costa L, Ali SM, Demers LM 2001 Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181185.
  • 50
    Carter JH, Hugo ER, Holdern T, Porco M, Fritz D 2001 Cysteine protease and cysteine protease inhibitor expression in prostate cancer cell lines. Cancer Res 42:403.
  • 51
    Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL 2002 Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52:2033.
  • 52
    Yoshida E, Verrusio EN, Mihara H, Oh D, Kwaan HC 1994 Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 54:33003304.
  • 53
    Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL 2001 Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611616.
  • 54
    Granchi S, Brocchi S, Bonaccorse L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M 2001 Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49:267277.
  • 55
    Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ 1994 Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines. Urology 43:675679.